Equibles does not estimate personal net worth.
Get an email with a short summary when Agios Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get AGIO alertsCecilia Jones is recorded as CFO at Agios Pharmaceuticals, Inc. (AGIO). The newest filing on record that lists Cecilia Jones as CFO at Agios Pharmaceuticals, Inc. (AGIO) is dated April 24, 2026. Agios Pharmaceuticals, Inc. reported in an 8-K filed September 19, 2022 that Cecilia Jones was appointed Chief Financial Officer, effective September 26, 2022. The proxy statement of Agios Pharmaceuticals, Inc. reports total compensation of $2,518,222 for Cecilia Jones in fiscal 2025, including a base salary of $535,085. Disclosed compensation is on record for 6 fiscal years. Cecilia Jones has spoken on 16 earnings calls and 1 other investor event across 1 company, most recently for Agios Pharmaceuticals, Inc. on September 9, 2026. Agios Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Agios Pharmaceuticals, Inc. includes Brian Goff (CEO and Board Member), Jacqualyn Fouse (CEO and Board Member), David P. Schenkein (Chairman) and 7 others.
“On September 15, 2022, the Board of Directors (the "Board") of Agios Pharmaceuticals, Inc. (the "Company") appointed Cecilia Jones as the Company's Chief Financial Officer effective as of September 26, 2022 (the "Effective Date").”
“Yeah, so we expect that to continue to be in that range of 10 to 20 percent as we've guided before. There's always some quarter over quarter variability, but in an aggregate, that's a range we still expect to see.”
“Yeah, so we expect that to continue to be in that range of 10 to 20 percent as we've guided before. There's always some quarter over quarter variability, but in an aggregate, that's a range we still expect to see.”
“As we have previously shared, we will report MetaPivot net revenues with U.S. and S.U.S. components. In the first quarter, we delivered $20.7 million in worldwide MetaPivot net revenues, with $18.8 million from sales generated in the U.S., driven by the recent launch of Agvesme in Thalassemia.”
“Our fourth quarter and full year 2025 financial results can be found in the press release issued earlier this morning and additional details can be found in our 10k which will be fired later today fourth quarter worldwide pyrocan revenue was 20 million dollars an increase of 86 percent compared to the fourth quarter…”
“Our third quarter 2025 financial results can be found in the press release issued this morning and additional details can be found in our 10-Q, which will be filed later today.”
Start not stated–present
Last confirmed April 24, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Agios Pharmaceuticals, Inc. (AGIO) | Chief Financial Officer | $535,085 | $2,518,222 |
| 2024 | Agios Pharmaceuticals, Inc. (AGIO) | Chief Financial Officer | $503,880 | $2,419,349 |
| 2023 | Agios Pharmaceuticals, Inc. (AGIO) | Chief Financial Officer | $484,500 | $1,208,784 |
| 2022 | Agios Pharmaceuticals, Inc. (AGIO) | Chief Financial Officer | $127,746 | $2,910,926 |
| 2021 | Agios Pharmaceuticals, Inc. (AGIO) | Chief Financial Officer | — | — |
| 2020 | Agios Pharmaceuticals, Inc. (AGIO) | Chief Financial Officer | — | — |
